Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $50.0K | — | — | $32.0K |
| Operating income | -$3.40M | -$4.03M | -$28.8M | -$4.28M |
| Operating margin | -6808.0% | — | — | -13381.3% |
| Net income | -$7.25M | -$4.34M | -$24.7M | -$11.8M |
| Net margin | -14510.0% | — | — | -36993.8% |
| EPS (diluted) | -$0.10 | -$0.07 | -$2.30 | -$0.38 |
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Operating cash flow | -$2.24M | -$2.85M | -$2.85M | -$1.89M |
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Cash & equivalents | $2.00K | $1.00K | $2.00M | $3.00K |
| Total assets | $46.5M | $44.6M | $20.3M | $17.4M |
| Total liabilities | $13.8M | $16.4M | $13.1M | $1.85M |
| Shareholders' equity | $29.6M | $25.2M | $4.26M | $12.6M |
| Retained earnings | -$8.63M | -$13.0M | -$37.7M | -$49.5M |
| Shares (wtd avg diluted) | 70.5M | 60.2M | 10.8M | 31.6M |
Every figure is extracted from IMPACT BIOMEDICAL INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.